A.I. Burnasyan  FMBC clinical bulletin. 2023 № 1

 

A.A. Slusar¹, P.A. Muraveva², M.V. Balyasin³

Experience with Levilimab in Ambulatory Practice (in the Provision of Primary Medical and Social Care)

¹A.I. Burnasyan Federal Medical Biophysical Center, Moscow, Russia
²Institute of Biological Systems named after Berezin Sergei, Moscow, Russia
³Peoples Friendship University of Russia, Moscow

Contact person: Slusar Anna Andreevna: ann.slusar@yandex.ru

Abstract
Purpose: The aim of the study was to confirm the effectiveness of the drug at the pre–hospital stage to prevent the development of severe forms of infection requiring hospitalization.
Materials and methods: To collect clinical and epidemiological data in the 2021-2022 season, an active prospective cohort study approach was used to assess the efficacy and safety of levilimab in patients with confirmed new coronavirus infection in outpatient settings. The comparison involved patients who received 1 or 2 doses of levilimab in combination with standard therapy (n=283) and patients who voluntarily refused to use levilimab and received only standard therapy (n=223).
Results: According to the study, patients who received levilimab (1 or 2 doses) had a lower frequency of hospitalizations compared to patients who had standard therapy taking into account the same laboratory indicators of CRP (mg/l) in the two study groups. Younger patients (under 30 years of age) had a much lower risk of hospitalization than older patients, regardless of the use of levilimab. There is also a direct correlation between the age of patients and their risk of hospitalization. It was revealed that with the refusal of the use of the Levilimab monoclonal antibody, an increase in age for every 10 years affected an increase in the risk of hospitalization by up to 10%. Patients after 50 years who refused levilimab and took standard therapy were hospitalized several times more often than patients with the same therapy who performed levilimab injection. Patients who received one dose (162 mg) or two doses (324 mg) of the drug had the best effect of the therapy – they had the lowest frequency of hospitalizations compared to patients who voluntarily refused the administration of a monoclonal antibody. When refusing to use levilimab, the probability of hospitalization increased to 60%, which was crucial for those patients who did not have a single injection.

Keywords: monoclonal antibodies, levilimab, Сovid-19. ambulatory practice, hospitalization, s-rp, compication of a new coronavirus infection, proactive therapy

For citation: Slusar AA, Muraveva PA, Balyasin MV. Experience with Levilimab in Ambulatory Practice (in the Provision of Primary Medical and Social Care). A.I. Burnasyan Federal Medical Biophysical Center Clinical Bulletin. 2023.1:40-45. (In Russian) DOI: 10.33266/2782-6430-2023-1-40-45

REFERENCES

1. COVID-19 Weekly Epidemiological Update. World Helth Organization. 2022;91–1. URL: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19—11-may-2022.
2. Operational Report on the Execution of the Federal Budget and the Budget of State Extra-Budgetary Funds for January-December 2020. Bulletin of the Accounts Chamber of the Russian Federation. 2021;1:7. URL: https://ach.gov.ru/audit/ (In Russ.).
3. Ponomarev Yu.Yu., Makarov A.V., Borzykh K.A., Radchenko D.M. Monitoring the Coronavirus Pandemic for 2021. Monitoring Ekonomicheskoy Situatsii v Rossii: Tendentsii i Vyzovy Sotsialno-Ekonomicheskogo Razvitiya. 2022;1:5-8. URL: https://www.iep.ru/ru/doc/37043/monitoring-pandemii-koronavirusa-za-2021-god.pdf (In Russ.).
4. Otchet O Rezultatakh Deyatelnosti Federalnogo Fonda Obyazatelnogo Meditsinskogo Strakhovaniya v 2020 Godu = Report on the Results of the Activities of the Federal Compulsory Medical Insurance Fund in 2020. Moscow Publ., 2020. P. 13. URL: https://www.ffoms.gov.ru/system-oms/about-fund/fund-activities/1_ОТЧЕТ_о_результатах_деятельности_ФОМ С_за_2020_год.pdf (In Russ.).
5. Hwang Y.C., Lu R.M., Su S.C., et al. Monoclonal Antibodies for COVID-19 Therapy and SARS-CoV-2 Detection. J. Biomed Sci. 2022;29;1:1. doi:10.1186/s12929-021-00784-w.
6. Furlow B. COVACTA Trial Raises Questions about Tocilizumab’s Benefit in COVID-19. Lancet Rheumatol. 2020;2;10:e592.
7. Capra R., De Rossi N., Mattioli F., Romanelli G., Scarpazza C., Sormani M.P., et al. Impact of Low Dose Tocilizumab on Mortality Rate in Patients with COVID-19 Related Pneumonia. Eur. J. Intern. Med. 2020;76:31–35.
8. Hermine O., Mariette X., Tharaux P.L., Resche-Rigon M., Porcher R., Ravaud P., et al. Effect of Tocilizumab VS Usual Care in Adults Hospitalized with COVID-19 and Moderate or Severe Pneumonia: a Randomized Clinical Trial. JAMA Intern. Med. 2021;181;1:32–40.
9. Investigators R.-C., Gordon A.C., Mouncey P.R., Al-Beidh F., Rowan K.M., Nichol A.D., et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N. Engl. J. Med. 2021;384;16:1491–1502.
10. Zeraatkar D., Cusano E., Martinez J.P.D., Qasim A., Mangala S.O., Kum E., et al. Tocilizumab and Sarilumab Alone or in Combination with Corticosteroids for COVID-19: a Systematic Review and Network Meta-Analysis. medRxiv. 2021:21259867. URL: https://doi.org/10.1101/2021.07.05.21259867.
11. Khlyabova P., Eremeeva A., Lutckii A., Dokukina E., Chernyaeva E., Ivanov R. SAT0040 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Bcd-089, Novel Monoclonal Anti-il-6 Receptor Antibody: Results from the First-in-Human Single Dose Escalation Study in Healthy Volunteers. Ann. Rheum. Dis. 2018;77;2:884.2-885.

Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 11.11.2022. Accepted for publication: 30.09.2022